Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a
clinical-stage oncology company developing innovative, full-length
multispecific antibodies (Biclonics® and Triclonics®), today
announced financial results for the second quarter and provided a
business update.
“Receiving Fast Track Designation is an important milestone for
petosemtamab, which we believe further validates its potential to
address the unmet need of patients with previously treated
recurrent or metastatic head and neck cancer,” said Bill Lundberg,
M.D., President, Chief Executive Officer of Merus. “We also believe
the robust clinical data observed in previously treated HNSCC
support a phase 3 trial of petosemtamab monotherapy in this
setting, which could potentially start in mid-2024. Additionally,
we are encouraged by our progress to date with the combination of
petosemtamab and Keytruda® as potential front-line therapy in
advanced HNSCC, and are evaluating a phase 3 trial in this setting
as well.”
Petosemtamab (MCLA-158: EGFR x LGR5 Biclonics®): Solid
TumorsGranted Fast Track Designation (FTD) for the
treatment of patients with recurrent or metastatic head & neck
squamous cell carcinoma (HNSCC), enrollment continues in dose
expansion in the phase 1/2 trial with petosemtamab monotherapy in
previously treated HNSCC, as well as in combination with Keytruda®
(pembrolizumab) as front-line therapy.
Petosemtamab is in clinical development in the expansion part of
a phase 1/2 open-label, multicenter trial evaluating petosemtamab
monotherapy in patients with advanced solid tumors, including
previously treated (recurrent or metastatic) HNSCC. Enrollment is
also ongoing in a cohort investigating petosemtamab in combination
with Keytruda® in patients with untreated HNSCC to evaluate the
safety and clinical activity in this population. Merus plans to
report initial interim clinical data from this cohort in the first
half of 2024.
Initiation of potential registration-enabling trial
Merus is enrolling up to a total of approximately 40 patients in
previously treated (2L/3L) HNSCC with petosemtamab monotherapy at
the 1100 or 1500 mg dose levels to confirm a suitable dose for
future randomized trials. Based on these data and additional
information and analyses, Merus anticipates potentially initiating
a randomized phase 3 trial of petosemtamab monotherapy, or
investigators’ choice of single agent chemotherapy or cetuximab in
2L/3L HNSCC. Merus anticipates such a trial could potentially start
in mid-2024. Merus believes a randomized registration trial in
HNSCC with an overall response rate (ORR) endpoint could
potentially support accelerated approval and the overall survival
(OS) results from the same study could potentially verify its
clinical benefit to support regular approval.
Merus is also evaluating a phase 3 trial investigating
petosemtamab with Keytruda® as a potential front-line therapy for
advanced HNSCC expressing PD-L1 (CPS > 1), pending analysis of
additional data on the tolerability and safety of the drug
combination.
Fast Track Designation
The U.S. Food & Drug Administration (FDA) has granted FTD
for petosemtamab for the treatment of patients with recurrent or
metastatic HNSCC whose disease has progressed following treatment
with platinum-based chemotherapy and an anti-programmed cell death
protein 1 (anti-PD-1) antibody.
FTD is designed to facilitate the development and expedite the
review of drugs to treat serious conditions and fill unmet medical
needs.
Interim data from AACR
In April, Merus provided an interim clinical update at the
American Association for Cancer Research (AACR) Annual Meeting
2023. As of a February 1, 2023 data cutoff date, 49
previously treated HNSCC patients were treated with petosemtamab at
the initial recommended phase 2 dose of 1500 mg intravenously every
two weeks. The ORR, in 43 evaluable patients, was 37.2% by Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1. per investigator
assessment. Median duration of response was 6.0 months and median
progression free survival was 5.3 months. 63% of responders had an
ongoing response at the data cutoff date. Median OS was 11.5
months. Petosemtamab continued to demonstrate a manageable safety
profile.
Zenocutuzumab (Zeno or MCLA-128: HER2 x HER3
Biclonics®): NRG1 fusion (NRG1+) cancer and other solid
tumorsGranted Breakthrough Therapy Designation (BTD) for
both NRG1+ non-small cell lung cancer (NSCLC) and NRG1+ pancreatic
cancer; enrollment continues in the eNRGy trial of Zeno monotherapy
in NRG1+ cancer and a phase 2 trial of Zeno in combination with
androgen deprivation therapy (ADT) in castration resistant prostate
cancer (CRPC); as well as in combination with afatinib in NRG1+
non-small cell lung cancer (NSCLC)
The FDA has granted BTD to Zeno for the treatment of patients
with advanced unresectable or metastatic NRG1+ pancreatic cancer
following progression with prior systemic therapy or who have no
satisfactory alternative treatment options. Additionally, the FDA
has granted BTD to Zeno for the treatment of patients with advanced
unresectable or metastatic NRG1+ NSCLC, following progression with
prior systemic therapy. Zeno is being investigated in the phase 1/2
eNRGy trial and Early Access Program (EAP) which are assessing the
safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer
(Phase 1/2: NCT02912949, EAP: NCT04100694).
As of June 2023, more than 175 patients with NRG1+ cancer have
been treated with Zeno monotherapy. The company continues to work
with the FDA and is focused on accumulating data to support a
potential Biologics License Application.
Merus believes that obtaining a commercialization partnership
agreement will be an essential step in bringing Zeno to patients
with NRG1+ cancer, if approved.
Merus plans to present a clinical update on Zeno in NRG1+ cancer
at the European Society for Medical Oncology (ESMO) 2023 taking
place in Madrid, Spain October 20-24, 2023. The presentations will
consist of a mini-oral lecture titled: Durable efficacy of
zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1
fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) and a
poster presentation titled: Durable efficacy of zenocutuzumab, a
HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive
(NRG1+) pancreatic ductal adenocarcinoma (PDAC).
Further, Merus is evaluating Zeno in combination with an ADT
(enzalutamide or abiraterone) in men with CRPC, irrespective of
NRG1+ status. Merus plans to provide initial clinical data on Zeno
in CRPC in the second half of 2023.
Merus is also evaluating Zeno in combination with afatinib in
patients with NRG1+ NSCLC.
MCLA-129 (EGFR x c-MET Biclonics®): Solid
TumorsEnrollment continues in the expansion cohorts in the
phase 1/2 trial; clinical update planned for 2H23
MCLA-129 is in clinical development in a phase 1/2, open-label
clinical trial evaluating MCLA-129 monotherapy in patients with
EGFR ex20 NSCLC, MET ex14 NSCLC, and in HNSCC, as well as MCLA-129
in combination with Tagrisso®, a third generation EGFR TKI, in
patients with treatment-naïve EGFR mutant (m) NSCLC and in patients
with EGFRm NSCLC that have progressed on Tagrisso®.
In April, Merus provided a pre-clinical presentation of MCLA-129
in comparison with amivantamab at the AACR Annual Meeting 2023. The
Company plans to provide an initial clinical data update from the
expansion cohorts, and a further clinical development strategy
update in the second half of 2023.
MCLA-129 is subject to a collaboration and license agreement
with Betta Pharmaceuticals Co. Ltd. (Betta), which permits Betta to
develop MCLA-129 and potentially commercialize exclusively in
China, while Merus retains global rights outside of China.
In July, the National Medical Products Administration in China
approved the investigational new drug application permitting Betta
to investigate the combination of MCLA-129 and befotertinib, a
third generation EGFR tyrosine kinase inhibitor, in adult patients
in China that have locally advanced or metastatic NSCLC, with an
EGFR Exon 19 deletion mutation or Exon 21 (L858R) substitution
mutation.
MCLA-145 (CD137 x PD-L1 Biclonics®): Solid
TumorsEnrollment continues in the phase 1 trial, including
in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor
MCLA-145 is in clinical development in a global, phase 1,
open-label, clinical trial evaluating MCLA-145 in patients with
solid tumors. The trial is in the dose expansion phase evaluating
the combination of MCLA-145 with Keytruda®, with enrollment
ongoing.
Collaborations
Incyte CorporationSince 2017, Merus has been
working with Incyte Corporation (Incyte) under a global
collaboration and license agreement focused on the research,
discovery and development of bispecific antibodies utilizing Merus’
proprietary Biclonics® technology platform. The agreement grants
Incyte certain exclusive rights for up to ten bispecific and
monospecific antibody programs. The collaboration is progressing,
with multiple programs in various stages of preclinical and
clinical development. For each program under the collaboration,
Merus receives reimbursement for research activities and is
eligible to receive potential development, regulatory and
commercial milestones and sales royalties for any products, if
approved. Further, Incyte announced, in 2023, that INCA33890, a
novel TGFBr2xPD1 bispecific antibody developed through the
collaboration is currently being evaluated in clinical studies. In
July 2023, Merus achieved a milestone and expects a payment of $2.5
million related to the advancement of this program in the third
quarter of 2023.
Loxo Oncology at LillyIn January
2021, Merus and Loxo Oncology at Lilly, a research and
development group of Eli Lilly and Company (Lilly), announced a
research collaboration and exclusive license agreement to develop
up to three CD3-engaging T-cell re-directing bispecific antibody
therapies utilizing Merus’ Biclonics® platform and proprietary
CD3 panel along with the scientific and rational drug design
expertise of Loxo Oncology at Lilly. The collaboration is
progressing with multiple active research programs underway.
Cash Runway, existing cash, cash equivalents and
marketable securities expected to fund Merus’ operations into
2026As of June 30, 2023, Merus had $311.5 million cash,
cash equivalents and marketable securities. Based on the Company’s
current operating plan, the existing cash, cash equivalents and
marketable securities are expected to fund Merus’ operations into
2026.
Second Quarter 2023 Financial Results
We ended the second quarter with cash, cash equivalents and
marketable securities of $311.5 million compared
to $326.7 million at December 31, 2022.
Collaboration revenue for the three months ended June 30,
2023 decreased by $2.2 million as compared to the
three months ended June 30, 2022, primarily as a result of
decreases in reimbursement revenue of $0.5 million, milestone
revenue of $1.0 million and amortization of deferred revenue of
$0.7 million.
Research and development expense for the three months
ended June 30, 2023 decreased by $2.8
million as compared to the three months ended June 30,
2022, primarily as a result of decreases in external clinical
services and drug manufacturing costs, including costs to fulfill
our obligations under our collaboration agreements, related to our
programs of $3.8 million and a decrease in facilities costs of $0.5
million, partially offset by an increase in personnel related
expenses including stock-based compensation of $1.5 million due to
an increase in employee headcount.
General and administrative expense for the three months
ended June 30, 2023 increased by $3.4
million as compared to the three months
ended June 30, 2022, primarily as a result of increases
in facilities costs including depreciation of $1.6 million,
consulting costs of $1.2 million, IP and license costs of $0.4
million, and travel expenses of $0.4 million, partially offset by a
decrease in finance and human resources costs of $0.2 million.
Collaboration revenue for the six months
ended June 30, 2023 decreased by $0.3
million as compared to the six months ended June 30,
2022, primarily as a result of a decrease in reimbursement revenue
of $0.9 million, decrease of amortization of deferred revenue of
$0.9 million partially offset by an increase in milestone revenue
of $1.5 million.
Research and development expense for the six months
ended June 30, 2023 increased by $5.1
million as compared to the six months ended June 30,
2022, primarily as a result of increases in personnel related
expenses including stock-based compensation of $3.7 million,
external clinical services and drug manufacturing costs, including
costs to fulfill our obligations under our collaboration
agreements, related to our programs of $1.6 million, consulting
expenses of $0.6 million, and consumables expenses of $0.3 million
and travel costs of $0.2 million, partially offset by decreases in
facilities costs of $0.8 million and partner expenses of $0.5
million. General and administrative expense for the six months
ended June 30, 2023 increased by $7.0
million as compared to the six months ended June 30,
2022, primarily as a result of increases in consulting costs of
$3.6 million, facilities costs including depreciation of $2.8
million, travel costs of $0.6 million, personnel related expenses
including stock-based compensation of $0.5 million due to an
increase in employee headcount, and IP and license costs of $0.3
million, partially offset by decreases in finance and human
resources costs of $0.8 million.
Other income (loss), net consists of interest earned and fees
paid on our cash and cash equivalents held on account, accretion of
investment earnings and net foreign exchange (losses) gains on our
foreign denominated cash, cash equivalents and marketable
securities. Other gains or losses relate to the issuance and
settlement of financial instruments.
MERUS N.V. |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(UNAUDITED) |
(Amounts in thousands, except per share data) |
|
|
|
|
|
|
|
June 30,2023 |
|
|
December 31,2022 |
|
ASSETS |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ |
101,096 |
|
|
$ |
147,749 |
|
Marketable securities |
|
163,950 |
|
|
|
142,480 |
|
Accounts receivable |
|
2,836 |
|
|
|
4,051 |
|
Prepaid expenses and other current assets |
|
15,243 |
|
|
|
12,163 |
|
Total current assets |
|
283,125 |
|
|
|
306,443 |
|
Marketable securities |
|
46,501 |
|
|
|
36,457 |
|
Property and equipment, net |
|
13,049 |
|
|
|
12,222 |
|
Operating lease right-of-use
assets |
|
11,946 |
|
|
|
12,618 |
|
Intangible assets, net |
|
1,882 |
|
|
|
1,950 |
|
Deferred tax assets |
|
3,057 |
|
|
|
2,041 |
|
Other assets |
|
4,064 |
|
|
|
4,811 |
|
Total assets |
$ |
363,624 |
|
|
$ |
376,542 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
$ |
7,596 |
|
|
$ |
9,834 |
|
Accrued expenses and other liabilities |
|
31,143 |
|
|
|
35,590 |
|
Income taxes payable |
|
1,349 |
|
|
|
2,400 |
|
Current portion of lease obligation |
|
1,610 |
|
|
|
1,684 |
|
Current portion of deferred revenue |
|
24,151 |
|
|
|
29,418 |
|
Total current liabilities |
|
65,849 |
|
|
|
78,926 |
|
Lease obligation |
|
11,168 |
|
|
|
11,790 |
|
Deferred revenue, net of current
portion |
|
29,202 |
|
|
|
38,771 |
|
Total liabilities |
|
106,219 |
|
|
|
129,487 |
|
Commitments and contingencies -
Note 6 |
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
Common shares, €0.09 par value; 67,500,000 shares authorized at
June 30, 2023 and December 31, 2022; 49,853,659 and 46,310,589
shares issued and outstanding as at June 30, 2023 and
December 31, 2022, respectively |
|
5,099 |
|
|
|
4,751 |
|
Additional paid-in capital |
|
948,913 |
|
|
|
870,874 |
|
Accumulated other comprehensive income |
|
(26,711 |
) |
|
|
(30,448 |
) |
Accumulated deficit |
|
(669,896 |
) |
|
|
(598,122 |
) |
Total stockholders’ equity |
|
257,405 |
|
|
|
247,055 |
|
Total liabilities and
stockholders’ equity |
$ |
363,624 |
|
|
$ |
376,542 |
|
MERUS N.V. |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS |
(UNAUDITED) |
(Amounts in thousands, except per share data) |
|
|
|
|
|
|
|
Three Months
EndedJune 30, |
|
|
Six Months
EndedJune 30, |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Collaboration revenue |
$ |
10,476 |
|
|
$ |
12,684 |
|
|
$ |
23,975 |
|
|
$ |
24,339 |
|
Total revenue |
|
10,476 |
|
|
|
12,684 |
|
|
|
23,975 |
|
|
|
24,339 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
28,298 |
|
|
|
31,096 |
|
|
|
63,163 |
|
|
|
58,071 |
|
General and administrative |
|
16,063 |
|
|
|
12,695 |
|
|
|
31,449 |
|
|
|
24,448 |
|
Total operating expenses |
|
44,361 |
|
|
|
43,791 |
|
|
|
94,612 |
|
|
|
82,519 |
|
Operating loss |
|
(33,885 |
) |
|
|
(31,107 |
) |
|
|
(70,637 |
) |
|
|
(58,180 |
) |
Other income, net: |
|
|
|
|
|
|
|
|
|
|
|
Interest income, net |
|
2,795 |
|
|
|
316 |
|
|
|
4,790 |
|
|
|
422 |
|
Foreign exchange gains (loss) |
|
551 |
|
|
|
24,607 |
|
|
|
(4,890 |
) |
|
|
32,337 |
|
Other gains, net |
|
— |
|
|
|
601 |
|
|
|
— |
|
|
|
1,059 |
|
Total other income (loss),
net |
|
3,346 |
|
|
|
25,524 |
|
|
|
(100 |
) |
|
|
33,818 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss before income taxes |
|
(30,539 |
) |
|
|
(5,583 |
) |
|
|
(70,737 |
) |
|
|
(24,362 |
) |
Income tax expense |
|
1,494 |
|
|
|
131 |
|
|
|
1,037 |
|
|
|
245 |
|
Net loss |
$ |
(32,033 |
) |
|
$ |
(5,714 |
) |
|
$ |
(71,774 |
) |
|
$ |
(24,607 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
Currency translation adjustment |
|
(505 |
) |
|
|
(19,921 |
) |
|
|
3,737 |
|
|
|
(25,969 |
) |
Comprehensive loss |
$ |
(32,538 |
) |
|
$ |
(25,635 |
) |
|
$ |
(68,037 |
) |
|
$ |
(50,576 |
) |
Net loss per share attributable
to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.66 |
) |
|
$ |
(0.13 |
) |
|
$ |
(1.52 |
) |
|
$ |
(0.56 |
) |
Weighted-average common shares
outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
48,321,708 |
|
|
|
43,636,337 |
|
|
|
47,328,259 |
|
|
|
43,781,195 |
|
About Merus N.V.Merus is a clinical-stage
oncology company developing innovative full-length human bispecific
and trispecific antibody therapeutics, referred to as
Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website, Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation, statements regarding the content and
timing of clinical trials, data readouts and clinical, regulatory,
strategy and development updates for our product candidates; Merus’
belief that receipt of FTD for petosemtamab validates its potential
to address the unmet need of patients with previously treated
recurrent or metastatic HNSCC; Merus’ belief that the robust
clinical data observed in previously treated HNSCC support a phase
3 trial of petosemtamab monotherapy in patients with previously
treated head and neck cancer, which could potentially start in
mid-2024; the progress to date with the combination of petosemtamab
and Keytruda® as potential front-line therapy in advanced head and
neck cancer; Merus’ anticipation of potentially initiating a
randomized phase 3 trial of petosemtamab monotherapy, or
investigators’ choice of single agent chemotherapy or cetuximab in
2L/3L HNSCC; the potential design and details of such a phase 3
trial; the enrollment of approximately 40 patients in previously
treated HNSCC with petosemtamab monotherapy at the 1100 or 1500 mg
dose levels to confirm a suitable dose for future randomized
trials; Merus’ consideration of conducting a phase 3 trial in
front-line therapy in advanced head and neck cancer; the planned
interim clinical data update in the first half of 2024 concerning
the combination of petosemtamab with Keytruda® in front-line HNSCC;
the potential benefits of FTD for petosemtamab and BTD designations
for Zeno and the ability of Merus to maintain such designations;
Merus’ belief that a obtaining a commercialization partnership
agreement will be an essential step in bringing Zeno to patients
with NRG1+ cancer, if approved; the planned presentations of Zeno
at ESMO 2023; any planned updates on Zeno and NRG1+ cancer, and
Zeno in combination with an ADT for the potential treatment of
CRPC; statements regarding the sufficiency of our cash, cash
equivalents and marketable securities, and expectation that it will
fund the Company into 2026; the advancement of the phase 1 trial of
MCLA-145, as monotherapy and in combination with Keytruda®; the
advancement of the phase 1/2 trial for MCLA-129 in the dose
expansion phase, in monotherapy in Met ex14 NSCLC, EGFR ex20 NSCLC,
and in HNSCC, as well as in combination with Tagrisso® in treatment
naïve EGFRm NSCLC and in patients with EGFRm NSCLC that have
progressed on Tagrisso®; the design and treatment potential of our
bispecific antibody candidates and impact of their preclinical
data; the benefits of the collaboration between Loxo Oncology at
Lilly and Merus, its potential for future value generation,
including whether and when Merus will receive any future payment
under the collaboration, including milestones or royalties, and the
amounts of such payments; whether any programs under the
collaboration will be successful; Merus’ and Lilly’s activities
under the agreement; our global collaboration and license agreement
with Incyte, its progress and potential development and
commercialization of up to ten bispecific and monospecific
antibodies from our Biclonics® platform and Incyte’s clinical study
of INCA33890 developed in collaboration with us, including whether
and when Merus will receive any future payment under the
collaboration, including milestones or royalties, and the amounts
of such payments; whether any programs under the collaboration will
be successful; and our collaboration and license agreement with
Betta, which permits Betta to develop MCLA-129 and potentially
commercialize exclusively in China, while Merus retains full
ex-China rights, including any future clinical development by Betta
of MCLA-129 alone or in combination with befotertinib, a third
generation EGFR tyrosine kinase inhibitor. These forward-looking
statements are based on management’s current expectations. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following: our need
for additional funding, which may not be available and which may
require us to restrict our operations or require us to relinquish
rights to our technologies or antibody candidates; potential delays
in regulatory approval, which would impact our ability to
commercialize our product candidates and affect our ability to
generate revenue; the lengthy and expensive process of clinical
drug development, which has an uncertain outcome; the unpredictable
nature of our early stage development efforts for marketable drugs;
potential delays in enrollment of patients, which could affect the
receipt of necessary regulatory approvals; our reliance on third
parties to conduct our clinical trials and the potential for those
third parties to not perform satisfactorily; impacts of the
COVID-19 pandemic; we may not identify suitable Biclonics® or
bispecific antibody candidates under our collaborations or our
collaborators may fail to perform adequately under our
collaborations; our reliance on third parties to manufacture our
product candidates, which may delay, prevent or impair our
development and commercialization efforts; protection of our
proprietary technology; our patents may be found invalid,
unenforceable, circumvented by competitors and our patent
applications may be found not to comply with the rules and
regulations of patentability; we may fail to prevail in potential
lawsuits for infringement of third-party intellectual property; our
registered or unregistered trademarks or trade names may be
challenged, infringed, circumvented or declared generic or
determined to be infringing on other marks; and risks related to
our ceasing to qualify as an emerging growth company and a smaller
reporting company after December 31, 2021.
These and other important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-Q for the period
ended June 30, 2023, filed with the Securities and Exchange
Commission, or SEC, on August 7, 2023, and our other reports filed
with the SEC, could cause actual results to differ materially from
those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change, except as required
under applicable law. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent
to the date of this press release.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Investor Relations and Corporate Communications
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From Apr 2024 to May 2024
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From May 2023 to May 2024